clinical trial · NCT07301450
An Expanded Access Program of Garetosmab in Adult Patients With Fibrodysplasia Ossificans Progressiva (FOP)
Fibrodysplasia Ossificans Progressiva (FOP)Garetosmab
brief summary
The objective of this Expanded Access Program (EAP) is to provide garetosmab to patients with Fibrodysplasia Ossificans Progressiva (FOP) who have completed the double-blind treatment period of the parent study, OPTIMA (R2477-FOP-2175 \[NCT05394116\]), prior to marketing authorization approval, unless otherwise specified by country specific regulations for rare diseases.
started
—
primary completion
—
completion
—
last updated
Dec 24, 2025
detailed description
The program will enroll approximately up to 55 patients, globally.
official title
An Expanded Access Program of Garetosmab in Patients With Fibrodysplasia Ossificans Progressiva
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol